Zeqi Zhou

Title: Zeqi Zhou: Innovator in Prostate Cancer Diagnostics

Introduction

Zeqi Zhou is a notable inventor based in New City, NY (US). He has made significant contributions to the field of medical diagnostics, particularly in the area of prostate cancer detection. With a total of 3 patents to his name, Zhou's work has the potential to improve patient outcomes and reduce unnecessary medical procedures.

Latest Patents

Zhou's latest patents include innovative methods for determining complexed forms of immunologically determinable prostate-specific antigen (cPSA) in blood samples. One of his key inventions is a sandwich immunoassay that allows for the measurement of cPSA levels while rendering free PSA (fPSA) immunologically nondetectable. This method employs three anti-PSA antibodies, enabling highly sensitive and specific diagnosis and monitoring of prostate cancer. Another significant patent focuses on differentiating prostate cancer from benign prostatic hyperplasia (BPH) by assaying PSA-ACT, further enhancing the accuracy of prostate cancer diagnostics.

Career Highlights

Zeqi Zhou is currently associated with Bayer Corporation, where he continues to advance his research and innovations in medical diagnostics. His work has garnered attention for its potential to aid in the diagnosis and monitoring of prostate cancer, significantly reducing the need for unnecessary prostate biopsies.

Collaborations

Zhou collaborates with esteemed colleagues such as William Jeffrey Allard and Kwok K Yeung, contributing to a dynamic research environment that fosters innovation and development in the field of medical diagnostics.

Conclusion

Zeqi Zhou's contributions to prostate cancer diagnostics through his innovative patents highlight his role as a leading inventor in the medical field. His work not only enhances diagnostic accuracy but also has the potential to improve patient care significantly.